BRPI0908098A2 - Beloxepine, composition, methods for treating pain in a mammal, for inhibiting ne reuptake, for antagonizing a 5ht2 receptor, and for treating a disorder in a patient who is responsive to treatment with a nri compound and a 5ht2 antagonist compound - Google Patents

Beloxepine, composition, methods for treating pain in a mammal, for inhibiting ne reuptake, for antagonizing a 5ht2 receptor, and for treating a disorder in a patient who is responsive to treatment with a nri compound and a 5ht2 antagonist compound

Info

Publication number
BRPI0908098A2
BRPI0908098A2 BRPI0908098-8A BRPI0908098A BRPI0908098A2 BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2 BR PI0908098 A BRPI0908098 A BR PI0908098A BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2
Authority
BR
Brazil
Prior art keywords
treating
compound
beloxepine
antagonizing
reuptake
Prior art date
Application number
BRPI0908098-8A
Other languages
Portuguese (pt)
Inventor
Bertrand Le Bourdonnec
Roland Dolle
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of BRPI0908098A2 publication Critical patent/BRPI0908098A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
BRPI0908098-8A 2008-02-19 2009-02-19 Beloxepine, composition, methods for treating pain in a mammal, for inhibiting ne reuptake, for antagonizing a 5ht2 receptor, and for treating a disorder in a patient who is responsive to treatment with a nri compound and a 5ht2 antagonist compound BRPI0908098A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2991608P 2008-02-19 2008-02-19
US2991508P 2008-02-19 2008-02-19
US2991308P 2008-02-19 2008-02-19
US5092108P 2008-05-06 2008-05-06
PCT/US2009/034461 WO2009105507A2 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Publications (1)

Publication Number Publication Date
BRPI0908098A2 true BRPI0908098A2 (en) 2015-08-18

Family

ID=40986169

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908098-8A BRPI0908098A2 (en) 2008-02-19 2009-02-19 Beloxepine, composition, methods for treating pain in a mammal, for inhibiting ne reuptake, for antagonizing a 5ht2 receptor, and for treating a disorder in a patient who is responsive to treatment with a nri compound and a 5ht2 antagonist compound

Country Status (11)

Country Link
EP (1) EP2285818A4 (en)
JP (1) JP2011512414A (en)
KR (1) KR20100137473A (en)
CN (1) CN102007139A (en)
AU (1) AU2009215541A1 (en)
BR (1) BRPI0908098A2 (en)
CA (1) CA2715192A1 (en)
IL (1) IL207668A0 (en)
MX (1) MX2010009110A (en)
NZ (2) NZ594937A (en)
WO (1) WO2009105507A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
PL3261640T3 (en) 2015-02-25 2022-10-31 The Regents Of The University Of California 5ht agonists for treating epilepsy disorders
CN106243096B (en) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 The new application of tricyclic drugs
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62754B1 (en) 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
EA200500783A1 (en) * 2002-12-11 2005-12-29 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи COMBINATION FOR THE TREATMENT OF ATTENTION DEFICIENCY SYNDROME WITH HYPERACTIVITY
CA2543710A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
CA2588595A1 (en) * 2004-12-13 2006-06-22 Arena Pharmaceuticals, Inc. N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
JP4937141B2 (en) * 2005-01-27 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Heterocyclic tetracyclic tetrahydrofuran derivatives as 5HT2 inhibitors in the treatment of CNS disorders
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
RU2008110082A (en) * 2005-09-29 2009-11-10 Вайет (Us) DERIVATIVES OF BENZOTIADIAZOLIPHENYLALKYLAMINE FOR THE TREATMENT OF THE CONDITIONS AIMED BY THE REVERSION OF MONOAMINE
CA2647835A1 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
GB0608655D0 (en) * 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes

Also Published As

Publication number Publication date
KR20100137473A (en) 2010-12-30
NZ594937A (en) 2013-03-28
NZ587896A (en) 2011-09-30
WO2009105507A2 (en) 2009-08-27
IL207668A0 (en) 2010-12-30
CN102007139A (en) 2011-04-06
WO2009105507A3 (en) 2010-01-14
MX2010009110A (en) 2010-11-30
EP2285818A2 (en) 2011-02-23
EP2285818A4 (en) 2011-08-17
AU2009215541A1 (en) 2009-08-27
CA2715192A1 (en) 2009-08-27
JP2011512414A (en) 2011-04-21

Similar Documents

Publication Publication Date Title
IL243574B (en) Pharmaceutical composition for use in treating a disorder treatable by purine receptor blocking
HK1202429A1 (en) Methods for prevention and treatment of acute renal injury
EP2229171A4 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
BR112013013417A2 (en) compound, medicament, methods for inhibiting acetylco carboxylase in a mammal, and for prophylaxis or treatment of obesity or diabetes in a mammal, and use of a compound or salt
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
HK1165294A1 (en) Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
BRPI0812504A2 (en) Compound, pharmaceutical composition and method of prophylaxis or treatment of cannabinoid receptor-associated disease or condition in a mammalian subject
BRPI0917004A2 (en) compound, pharmaceutical composition, use of a compound, and methods for improving sleep quality, treating insomnia, and treating or controlling obesity in a mammalian patient in need thereof
BRPI0916890A2 (en) compound, pharmaceutical composition, methods for eliciting an agonist effect, and an antagonist effect of a gip receptor, for treating conditions or diseases, for treating disorders, for treating or preventing secondary causes of diabetes, and for stimulating insulin secretion in an individual , and, use of a compound
BR112013025386A2 (en) combination of a compound, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a braf v600e mutation-modulated disease or disorder and high levels of pakt in a mammal and use
MX2011008450A (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof.
EP2389227A4 (en) Methods for treating acute myocardial infarctions and associated disorders
BRPI1013705A2 (en) compounds, pharmaceutical composition, method of treating disease or condition associated with trap1 function and uses of compounds and pharmaceutical composition
BRPI0811845A2 (en) DOSAGE FORM, AND METHODS FOR PREPARING DOSAGE, AND TREATMENT OF A BAD CONDITION IN A PATIENT
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
BR112013016862A2 (en) combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
HRP20180531T1 (en) Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
EP2190408A4 (en) Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
BR112012002246A2 (en) acceptable pharmaceutical compound, compound or salt thereof, pharmaceutical composition, method for inhibiting, treating and / or reducing cognitive decline and / or akzhmer's disease in a patient
EP2300015A4 (en) Use of gabaa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
SI2355822T1 (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzosbcthiophene-2-carboxamide and pharmaceutically acceptable salts thereof
BRPI0912112A2 (en) agent for suppressing an undesirable effect of an opioid analgesic, pain therapeutic and / or preventative agent, kit, pharmaceutical composition, methods for suppressing an undesirable effect of an opioid, and for treating and / or preventing pain, use of an compound and an opioid compound and combination
BRPI0908098A2 (en) Beloxepine, composition, methods for treating pain in a mammal, for inhibiting ne reuptake, for antagonizing a 5ht2 receptor, and for treating a disorder in a patient who is responsive to treatment with a nri compound and a 5ht2 antagonist compound
HK1232162A1 (en) Compounds for treating pain syndrome and other disorders
BR112013004707A2 (en) administration of an anti-obesity compound to individuals with renal impairment

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.